Weeks after California loss, J&J scores talc victory close to home

jnj
Johnson & Johnson's headquarters is less than a mile from the Middlesex County Superior Court, according to Google. (J&J)

Johnson & Johnson has suffered some costly setbacks in its talc defense, but on Wednesday, the company scored a victory close to home. 

A jury in Middlesex County, New Jersey, cleared the drugmaker in a lawsuit brought by plaintiff Ricardo Rimondi alleging J&J’s talc contains asbestos and caused his mesothelioma, Reuters reports. The 58-year-old resident of Brentwood, New York, who was born in Peru and came to the U.S. in 1992, said he used J&J's talc powder from birth until age 50, according to the the New Jersey Law Journal. Doctors diagnosed him with mesothelioma in 2016.

But the jury saw things differently. It delivered the verdict in favor of J&J unanimously in 30 minutes.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The decision underscores that “decades of clinical evidence and scientific studies by medical experts around the world support the safety of Johnson’s Baby Powder,” a J&J spokeswoman said. So far, out of nine mesothelioma/talc cases that have made it to trial, J&J has prevailed in three, she added. Five resulted in mistrials. 

Earlier this month, a California jury hit the company with a $29 million verdict in favor of the plaintiff; J&J pledged to appeal. The company reiterated on Wednesday that for each verdict against J&J that’s made it through appeals, each has been overturned. The company maintains its talc is safe and doesn't cause cancer.

RELATED: Johnson & Johnson chalks up another talc loss with $29M mesothelioma verdict 

Plaintiffs argue otherwise. About 13,000 have sued the company alleging harm from talc, according to a recent J&J securities filing.

Additionally on Wednesday, J&J settled three talc cases in Oklahoma, California and New York, Bloomberg reports. In a statement to the news service, a J&J spokeswoman described the deals as "one-off situations" where settling was a "reasonable alternative." 

The latest victory for J&J comes after some big losses in 2018. In July, jurors in St. Louis hit the company with a $4.69 billion verdict after a trial that combined the claims of 22 plaintiffs. J&J has appealed. In December, Reuters reported that the drugmaker has known about and worked to hide asbestos in its talc for decades. Investors sent J&J’s shares down sharply after the report, lopping tens of billions of dollars off its market cap. The company’s shares haven’t recovered to their levels from before the report. 

RELATED: Justice Department, SEC subpoenas put J&J's talc woes under federal microscope

After the Reuters report, Senator Patty Murray asked J&J for some documents related to the product, and the company disclosed that the Justice Department and SEC are looking into the issue.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.